Abvc Biopharma (ABVC) Non Operating Income (2015 - 2026)
Abvc Biopharma's (ABVC) quarterly Non Operating Income came in at -$30955.0 in Q2 2026, down 117.64% on a YoY basis from $175477.5 in Q2 2025, and up 73.65% quarter-over-quarter from -$117465.0 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Non Operating Income (2015 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Non Operating Income for 12 consecutive years, with -$30955.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income fell 117.64% year-over-year to -$30955.0; the trailing twelve-month figure through Jun 2026 stood at -$1.1 million (down 100.05% YoY), and the FY2025 full-year result was -$1.2 million, down 80.86% from the prior year.
- Non Operating Income advanced to -$30955.0 in Q2 2026 per ABVC's latest filing, from -$117465.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $8954.0 in Q1 2023 and bottomed at -$1.2 million in Q3 2023.
- Historically, Non Operating Income has averaged -$218787.6 across 5 years, with a median of -$91963.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 13353.52% in 2022, then soared 195.15% in 2023.
- Over 5 years, Non Operating Income stood at -$9410.0 in 2022, then tumbled by 39.89% to -$13164.0 in 2023, then plunged by 598.59% to -$91963.0 in 2024, then sank by 789.0% to -$817552.0 in 2025, then soared by 96.21% to -$30955.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$30955.0, -$117465.0, and -$817552.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | -30,955.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -30,955.00 |
| Mar 31, 2026 | -117,465.00 |
| Dec 31, 2025 | -817,552.00 |
| Sep 30, 2025 | -118,586.00 |
| Jun 30, 2025 | -14,223.00 |
| Mar 31, 2025 | -251,185.00 |
| Dec 31, 2024 | -91,963.00 |
| Sep 30, 2024 | -184,760.00 |
| Jun 30, 2024 | -298,199.00 |
| Mar 31, 2024 | -89,412.00 |
| Dec 31, 2023 | -13,164.00 |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -39,688.00 |
| Mar 31, 2023 | 8,954.00 |
| Mar 31, 2022 | -9,410.00 |
| Dec 31, 2021 | 557,105.00 |
| Sep 30, 2021 | 8,643.00 |
| Jun 30, 2021 | -77,005.00 |
| Mar 31, 2021 | 71.00 |
| Dec 31, 2020 | -204,920.00 |